CMS expands Medicare coverage for Personalis' NeXT Personal test to immunotherapy monitoring

Personalis, Inc.

CMS coverage now includes immunotherapy monitoring for late-stage solid tumor patients as of May 12, 2026.
NeXT Personal is an ultrasensitive liquid biopsy test; the expanded indication broadens the addressable patient population.
No financial impact or revenue guidance was disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.